Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell Mol Life Sci. 2010 Nov;67(21):3621-31. doi: 10.1007/s00018-010-0488-2. Epub 2010 Aug 31.

Small molecule inhibitors of DNA repair nuclease activities of APE1.

Author information

  • 1Laboratory of Molecular Gerontology, Biomedical Research Center, National Institute on Aging, NIH, IRP, 251 Bayview Boulevard, Baltimore, MD 21224, USA wilsonda@mail.nih.gov

Abstract

APE1 is a multifunctional protein that possesses several nuclease activities, including the ability to incise at apurinic/apyrimidinic (AP) sites in DNA or RNA, to excise 3'-blocking termini from DNA ends, and to cleave at certain oxidized base lesions in DNA. Pre-clinical and clinical data indicate a role for APE1 in the pathogenesis of cancer and in resistance to DNA-interactive drugs, particularly monofunctional alkylators and antimetabolites. In an effort to improve the efficacy of therapeutic compounds, such as temozolomide, groups have begun to develop high-throughput screening assays and to identify small molecule inhibitors against APE1 repair nuclease activities. It is envisioned that such inhibitors will be used in combinatorial treatment paradigms to enhance the efficacy of DNA-interactive drugs that introduce relevant cytotoxic DNA lesions. In this review, we summarize the current state of the efforts to design potent and selective inhibitors against APE1 AP site incision activity.

PMID:
20809131
[PubMed - indexed for MEDLINE]
PMCID:
PMC2956791
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk